Could a daily shot help control rare lung disease?

NCT ID NCT07601295

Not yet recruiting Disease control Sponsor: Stanford University Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tests whether adding tiprelestat (elafin) to standard care improves blood flow in the lungs for people with pulmonary arterial hypertension (PAH). About 90 adults with moderate to severe PAH will receive either a daily injection of tiprelestat or a placebo for 168 days. The main goal is to see if the drug lowers pulmonary vascular resistance, a key measure of disease severity.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: tiprelestat (also known as elafin)
What this could lead to: If it works, this could point toward a new add-on treatment to help control pulmonary arterial hypertension and improve blood flow in the lungs.
What could go wrong: This is an early phase 2 trial with only 90 people, so results may not apply to everyone. The drug is given as a daily injection, which could be inconvenient or cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PULMONARY ARTERIAL HYPERTENSION (PAH) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

pulmonary arterial hypertension

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PULMONARY ARTERIAL HYPERTENSION (PAH)

Contacts and locations

Locations

Brown University/Rhode Island Hospital

Providence, Rhode Island, 02904, United States
Duke University

Durham, North Carolina, 27710, United States
Harvard University / Brigham and Women's Hospital

Boston, Massachusetts, 02138, United States
Stanford University

Stanford, California, 94305, United States
The University of Arizona / Banner University Medical Center

Tucson, Arizona, 85719, United States
University of California, San Francisco

San Francisco, California, 94143, United States
University of Colorado (UCD) Anschutz

Aurora, Colorado, 80045, United States
University of Pennsylvania

Philadelphia, Pennsylvania, 19104, United States
University of Texas Southwestern

Dallas, Texas, 75390, United States
University of Washington

Seattle, Washington, 98195, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.